A Double-blind, Placebo-controlled, Randomised Withdrawal Study of 3 Month Duration in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.).
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Oct 2009 New trial record